Literature DB >> 12567093

Gentamicin tympanoclysis: effects on the labyrinthine sensory cells.

Daniel J Pender1.   

Abstract

OBJECTIVES: The objective of the study was to determine whether a selective vestibular hair cell toxicity with sparing of the cochlear hair cells could be achieved by infusing different concentrations of gentamicin into the middle ears of adult cats. STUDY
DESIGN: Prospective experimental animal study treating only the left ear of each cat, the right ear serving as individual control.
METHODS: Gentamicin solution at concentrations of either 30 or 3 mg/mL was infused daily into the left middle ear of adult cats until overt ataxia occurred. After 1 month or 6 months, each cat was killed and its temporal bones prepared for optical microscopy.
RESULTS: Animals treated with 30 mg/mL gentamicin until ataxic required a median of five daily doses. These animals had clear-cut cochlear basal turn hair cell losses accompanying toxic lesions in the utricle and cristae. In contrast, animals treated with 3 mg/mL gentamicin until ataxic required an average of 19 daily doses. These animals had lesions restricted to the utricle and cristae with sparing of the cochlea hair cells. Animals that failed to develop ataxia manifested neither lesions of the cochlear nor vestibular hair cells.
CONCLUSION: Gentamicin tympanoclysis in the cat animal model, using a dilute solution and continued once daily until clinical ataxia occurs, is capable of producing selective vestibular hair cell toxicity while sparing cochlea hair cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12567093     DOI: 10.1097/00005537-200302000-00026

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  Preliminary Results of a New Experimental Model for Intratympanic Treatment.

Authors:  Kamil Aykal; Fazıl Necdet Ardıç; Funda Tümkaya; Emrah Yücel; Mehri Akarsu; Cüneyt Orhan Kara; Emin Erdem
Journal:  Turk Arch Otorhinolaryngol       Date:  2018-12-01

2.  Intratympanic gentamicin treatment for Ménière's disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study.

Authors:  Hendrik G Bremer; Ingrid van Rooy; Bas Pullens; Carla Colijn; Inge Stegeman; Hester J van der Zaag-Loonen; Peter Paul van Benthem; Sjaak F L Klis; Wilko Grolman; Tjasse D Bruintjes
Journal:  Trials       Date:  2014-08-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.